Friday’s big three: an FDA gene-therapy approval with a “free in the U.S.” twist, a federal drug-cost agreement, and an AbbVie CRL tied to manufacturing.
Thursday: Dupixent pediatrics + the $9B Inhibrx bid-watch
Dupixent picked up a U.S. label in children aged 2–11 with uncontrolled chronic spontaneous urticaria, while Inhibrx’s oncology assets entered the bid-watch zone.
Lilly’s Kelonia deal resets in vivo CAR-T comps, Trump’s psychedelics order pulls review timing into focus, and Roche’s lupus filing puts a label expansion on the clock.
